JBIO
Aerovate Therapeutics Inc (JBIO)
Healthcare • NASDAQ • $25.81+6.56%
- Symbol
- JBIO
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $25.81
- Daily Change
- +6.56%
- Market Cap
- $1.27B
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $28.00
- 52W Low
- $6.57
- Analyst Target
- $30.14
- Dividend Yield
- N/A
- Beta
- N/A
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Company websiteResearch JBIO on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.